Zumutor develops NK cell checkpoint immunotherapies to enhance natural killer cell activity against tumors.
$7.3MSeries B
Investor undisclosed
A $7.3M Series B for NK cell immunotherapy signals that checkpoint modulation (beyond the saturated PD-1/PD-L1 space) is attracting serious capital—especially with Accel backing, which rarely touches biotech unless the science is differentiated. They're likely funding IND-enabling studies and early clinical work, which means the NK cell thesis has moved past pure R&D into validation. If you're building in adjacent cell therapy or checkpoint biology, this validates that investors are willing to fund the harder immunology problems when the mechanism is genuinely novel.